Enterocloster bolteae drives hyperglycemia-associated colorectal cancer cell proliferation via Rac/Rho-MSH6-Elongin C signaling pathway

Table 1 Clinical data, n (%)/mean ± SD

Characteristic	DM group (n = 8)	DM-CRC group (n = 11)	DM vs DM-CRC, P value	CRC group (n = 10)	Control group (n = 11)	P value
Age (years)	55.7 ± 10.4	56.3 ± 11.5	0.7812	59.3 ± 11.8	53.5 ± 10.6	0.151
Male gender	4 (50)	5 (45.5)	0.9175	6 (60)	6 (54.5)	0.053
Smoking	2 (25)	3 (27.3)	0.8550	3 (30)	4 (36.4)	0.051
Alcohol drinking	2 (25)	3 (27.3)	0.9175	3 (30)	3 (27.3)	0.193
Family history of CRC	2 (25)	2 (18.2)	0.9175	2 (20)	2 (18.2)	0.524
Family history of colorectal polyps	3 (37.5)	2 (27.3)	0.6580	4 (40)	2 (18.2)	0.030
Regular antidiabetic drugs use	7 (87.5)	7 (63.6)	0.2681	0	0	< 0.001
BMI (kg/m2)	24.4 ± 3.9	22.2 ± 3.6	0.2498	22.5 ± 3.7	23.5 ± 3.5	0.025
FPG (mmol/L)	9.8 ± 1.2	10.1 ± 1.3	0.7211	4.1 ± 1.2	5.3 ± 1.1	< 0.001
TG (mmol/L)	3.0 ± 0.9	1.5 ± 0.9	0.0036	1.8 ± 0.9	2.1 ± 0.9	0.030
TCH (mmol/L)	5.1 ± 1.3	4.7 ± 1.3	0.4478	4.8 ± 1.3	4.9 ± 1.3	0.627
LDL (mmol/L)	3.01 ± 0.9	3.01 ± 1.0	0.6217	3.01 ± 1.0	3.01 ± 1.0	0.766
HDL (mmol/L)	0.9 ± 0.4	0.8 ± 0.3	0.6307	1.0 ± 0.3	2.0 ± 0.3	< 0.001

DM: Diabetes mellitus; CRC: Colorectal cancer; BMI: Body mass index; FPG: Fasting plasma glucose; TG: Triglyceride; TCH: Total cholesterol; LDL: Low-density lipoprotein cholesterol; HDL: High-density lipoprotein cholesterol.